Corbus Pharmaceuticals Holdings, Inc. (CRBP)

34.25 +0.75 (+2.24%) 收市：04:00PM EDT

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 19

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yuval Cohen Ph.D.	CEO & Director	907.78k	無	1975
Mr. Sean F. Moran CPA, M.B.A.	Chief Financial Officer	609.28k	無	1958
Ms. Lindsey Smith	Head of Corporate Communications & Patient Advocacy	無	無	無
Ms. Christina Bertsch	Head of Human Resources	無	無	無
Dr. Dominic Smethurst M.A., M.D.	Chief Medical Officer	無	無	1975

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

公司管治

截至 2024年4月1日 止，Corbus Pharmaceuticals Holdings, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：9；董事會：4；股東權利：4；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。